Up in smoke? Vaping on the edge of banishment

Industry Insight
Jul.13.2022

The U.S. Food and Drug Administration (FDA) has paused a ban on the sale of Juul Labs’ e-cigarettes, saying it requires an additional review of the company’s marketing application.

 

This pause follows a federal appeals court’s decision a few weeks ago to stay — i.e. temporarily freeze — the FDA’s ban, following an appeal from Juul requesting an emergency review of the FDA’s order.

 

But the once-thriving company isn’t out of the woods just yet: The FDA has only paused the ban for reevaluation. It has not rescinded it.

 

Juul has always been in the spotlight, in part because of its prominent placement atop the e-cigarette chain, but with the company facing a potential demise, it could be the first casualty, with the rest of the vaping industry in the government’s sights.

 

Dr. Zubair Karim, assistant professor in the Department of Interdisciplinary Health Sciences at Augusta University, was a researcher on a study that looked at Juul e-cigarettes and how they elevate the risk of thrombosis and other complications in patients.

 

Up in smoke? Vaping on the edge of banishment

 

“Thrombosis is the formation of a blood clot, either partial or complete blockage, within blood vessels, whether venous or arterial, limiting the natural flow of blood,” Karim said.

 

“There are several complications depending on where the thrombosis is located. The most serious problems include stroke, heart attack and serious breathing problems, which is called pulmonary embolism. If the patients are not treated in a timely manner, it will lead to life-threatening conditions. However, progression of the disease can be prevented by following changes in our lifestyle such as increasing physical activity, quitting smoking, losing weight, eating a balanced diet, quitting junk food and managing other health conditions.”

 

With the ban on Juul products, could this result in a ban on other companies’ e-cigarette products as well, or was there something specifically about Juul that caused their ban?

 

“This is the first steps toward the banning of the e-cigarette, i.e., Juul, where the FDA took a significant and bold step,” Karim said.

 

“Gradually, this will open the path for banning of the other e-cigarette products. There are no differences in the Juul and other products, but Juul became more popular in our young generation. Many local and state jurisdictions have recently begun enacting laws that prohibit e-cigarette usage, although some state laws with comprehensive smoke-free laws will still allow for vaping to be permitted in bars and restaurants while prohibiting e-cigarettes in other indoor places.”

 

For years, e-cigarettes and vaping devices were seen as a “safer” alternative to traditional cigarettes, but with flavors and packaging that has attracted children to the fad, efforts have been renewed to look into the possible side effects.

 

“Both smoking and vaping have similar side effects and cause serious health risks in the long run. Scientists do not fully understand the long-term health effects of electronic cigarettes, yet science indicates that they are not a safe alternative to smoking,” said Karim.

 

“In the last several years it has been observed that vaping is growing in popularity among teenagers. Moreover, e-cigarettes contain a large dose of nicotine, a substance known to slow the development of brains in fetuses, children and teens. Furthermore, vaping involves breathing in aerosol that contains several chemicals, including nicotine and flavoring through an e-cigarette or other devices. Also, the liquid present in the e-cigarettes which creates the vapor is dangerous to adults and children if they swallow, inhale, or get it on the skin.

 

Nonetheless, vaping also delivers dangerous chemicals, including diacetyl, cancer-causing chemicals, heavy metals, volatile organic compounds, and such toxic chemicals that are not generated in traditional cigarettes. In summary, long-term vaping causes similar toxic impact to overall health compared to traditional cigarettes.”

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives
R.J. Reynolds Vapor Company Launches Flavored Vuse Pro Pods in U.S. Without FDA Marketing Authorization
R.J. Reynolds Vapor Company Launches Flavored Vuse Pro Pods in U.S. Without FDA Marketing Authorization
R.J. Reynolds Vapor Company has begun selling four flavored Vuse Pro pods — Peach, Berry, Watermelon and Fresh Mint — in Ohio and selected other U.S. markets. According to the Vuse U.S. FAQ, Vuse Pro contains approximately 5.0% nicotine by weight, and Vuse Pro pre-filled pods are intended for use with Vuse Alto devices. Reynolds told 2Firsts that product labeling lists an e-liquid capacity of 2.0 mL per pod. The Vuse Alto Power Unit received FDA marketing authorization in 2024, while the new Vuse Pro pods themselves have not received marketing granted orders. The rollout follows the FDA’s May 2026 revision of enforcement priorities for certain unauthorized vaping products with qualifying pending applications.
BAT
Sep.10
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30
U.S. Customs Plan to Require Foreign Export Declarations Could Deal ‘Devastating’ Blow to China’s Vape Exports, Logistics gl Expert Says
U.S. Customs Plan to Require Foreign Export Declarations Could Deal ‘Devastating’ Blow to China’s Vape Exports, Logistics gl Expert Says
A U.S. Customs and Border Protection proposal to collect foreign export declarations and other overseas customs documents could expose discrepancies in the value, classification and description of China-made vape shipments entering the United States. A veteran Chinese logistics professional told 2Firsts that the measure, if implemented, could undermine the all-inclusive shipping model used by some unauthorized vape exporters and push parts of the trade toward costlier underground channels. The risk extends beyond higher duties: accurately declared products may also be more readily identified as unauthorized e-cigarettes subject to FDA enforcement.
Special Report
Sep.07